{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:03:37Z","timestamp":1775847817050,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tokai University, Isehara Campus"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to evaluate the efficacy of intravitreal injections of ranibizumab (IVR) in treating zone II stage 2 retinopathy of prematurity with plus disease (ROP II2+) in preterm infants, focusing on two primary outcomes: reactivation and persistent avascular retina (PAR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study design<\/jats:title>\n            <jats:p>Retrospective and consecutive case series.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study reviewed the medical records of preterm infants treated with IVR at Tokai University hospital between December 2019 and September 2023. Data on reactivation, PAR, and other clinical outcomes were analyzed using generalized estimating equations to account for correlations between eyes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thirty eyes from 16 infants received IVR treatment. Following initial IVR all eyes achieved remission for over one year with IVR alone. Forty percent of these eyes required subsequent treatment due to reactivation, with a median reactivation time of 70\u00a0days. One year after initial IVR, PAR was observed in 11 out of the 30 eyes. Lower birth weight was associated with a tendency toward reactivation, and it also showed a significant correlation with the development of PAR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This research supports the effectiveness of IVR for ROP II2+ over a one-year period. The links between lower birth weight and both reactivation and PAR might guide refinements in therapeutic strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10384-025-01199-y","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T23:28:49Z","timestamp":1747351729000},"page":"543-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic outcomes of ranibizumab for zone ii stage 2 retinopathy of prematurity with plus disease"],"prefix":"10.1007","volume":"69","author":[{"given":"Yoshihiro","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"Suppl 1","key":"1199_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","volume":"74","author":"H Blencowe","year":"2013","unstructured":"Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(Suppl 1):35\u201349.","journal-title":"Pediatr Res"},{"key":"1199_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/archdischild-2016-310532","volume":"102","author":"AL Solebo","year":"2017","unstructured":"Solebo AL, Teoh L, Rahi J. Epidemiology of blindness in children. Arch Dis Child. 2017;102:853\u20137.","journal-title":"Arch Dis Child"},{"key":"1199_CR3","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1111\/apa.15197","volume":"109","author":"A Taner","year":"2020","unstructured":"Taner A, Tekle S, Hothorn T, Adams M, Bassler D, Gerth-Kahlert C. Higher incidence of retinopathy of prematurity in extremely preterm infants associated with improved survival rates. Acta Paediatr. 2020;109:2033\u20139.","journal-title":"Acta Paediatr"},{"key":"1199_CR4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382:1445\u201357.","journal-title":"Lancet"},{"key":"1199_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1084-2756(03)00119-2","volume":"8","author":"LE Smith","year":"2003","unstructured":"Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469\u201373.","journal-title":"Semin Neonatol."},{"key":"1199_CR6","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.ophtha.2012.02.040","volume":"119","author":"WC Wu","year":"2012","unstructured":"Wu WC, Lin RI, Shih CP, Wang NK, Chen YP, Chao AN, et al. Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity. Ophthalmology. 2012;119:1907\u201316.","journal-title":"Ophthalmology"},{"key":"1199_CR7","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.preteyeres.2021.101018","volume":"88","author":"AS Tsai","year":"2022","unstructured":"Tsai AS, Chou HD, Ling XC, Al-Khaled T, Valikodath N, Cole E, et al. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog Retin Eye Res. 2022;88:101018.","journal-title":"Prog Retin Eye Res"},{"key":"1199_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603\u201315.","journal-title":"N Engl J Med"},{"key":"1199_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394:1551\u20139.","journal-title":"Lancet"},{"key":"1199_CR10","doi-asserted-by":"crossref","unstructured":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684\u201394.","DOI":"10.1001\/archopht.121.12.1684"},{"key":"1199_CR11","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, et al. International classification of retinopathy of prematurity. Ophthalmology. 2021;128:e51\u201368.","journal-title":"Ophthalmology."},{"key":"1199_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.17305\/bb.2023.9829","volume":"24","author":"Y Xu","year":"2023","unstructured":"Xu Y, Deng G, Zhang J, Zhu J, Liu Z, Xu F, et al. Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis. Biomol Biomed. 2023;24:676\u201387.","journal-title":"Biomol Biomed."},{"key":"1199_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40272-020-00433-z","volume":"23","author":"A Lee","year":"2021","unstructured":"Lee A, Shirley M. Ranibizumab: a review in retinopathy of prematurity. Paediatr Drugs. 2021;23:111\u20137.","journal-title":"Paediatr Drugs."},{"key":"1199_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00417-023-06224-9","volume":"262","author":"M Zhou","year":"2024","unstructured":"Zhou M, Hashimoto K, Liu W, Cai Y, Liang J, Shi X, et al. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials. Graefes Arch Clin Exp Ophthalmol. 2024;262:1409\u201319.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1199_CR15","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017;37:710\u20137.","journal-title":"Retina"},{"key":"1199_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12886-023-02886-5","volume":"23","author":"JK Cao","year":"2023","unstructured":"Cao JK, Han T, Tang HY, Zhang S, Wang ZH, Feng ZC, et al. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity. BMC Ophthalmol. 2023;23:137.","journal-title":"BMC Ophthalmol"},{"issue":"44","key":"1199_CR17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1097\/IAE.0000000000004206","volume":"1","author":"J Strawbridge","year":"2024","unstructured":"Strawbridge J, Cheng JY, Gundlach BS, Gillespie T, Karmouta R, Khitri M, et al. Short-Term reactivation of retinopathy of prematurity following primary ranibizumab treatment. Retina. 2024;1(44):1945\u201351.","journal-title":"Retina"},{"key":"1199_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.18240\/ijo.2023.01.14","volume":"16","author":"FY Wu","year":"2023","unstructured":"Wu FY, Yu WT, Zhao DX, Pu W, Zhang X, Gai CL. Recurrence risk factors of intravitreal ranibizumab monotherapy in retinopathy of prematurity: a retrospective study at one center. Int J Ophthalmol. 2023;16:95\u2013101.","journal-title":"Int J Ophthalmol"},{"key":"1199_CR19","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1007\/s00417-022-05628-3","volume":"260","author":"F Xia","year":"2022","unstructured":"Xia F, Lyu J, Peng J, Zhao P. Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis. Graefes Arch Clin Exp Ophthalmol. 2022;260:2837\u201346.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1199_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","volume":"6","author":"BW Fleck","year":"2022","unstructured":"Fleck BW, Reynolds JD, Zhu Q, Lepore D, Marlow N, Stahl A, et al. Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW trial. Ophthalmol Retina. 2022;6:628\u201337.","journal-title":"Ophthalmol Retina."},{"key":"1199_CR21","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","volume":"40","author":"KP Ling","year":"2020","unstructured":"Ling KP, Liao PJ, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina. 2020;40:1793\u2013803.","journal-title":"Retina"},{"key":"1199_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","volume":"17","author":"S Ittiara","year":"2013","unstructured":"Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J aapos. 2013;17:323\u20135.","journal-title":"J aapos"},{"key":"1199_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jaapos.2023.05.008","volume":"27","author":"A Yasin","year":"2023","unstructured":"Yasin A, Sinha S, Smith R, Jain SF, Hejkal T, Rychwalski P. Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab. J aapos. 2023;27:236\u20139.","journal-title":"J aapos"},{"key":"1199_CR24","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s10792-021-02198-x","volume":"42","author":"K Fadakar","year":"2022","unstructured":"Fadakar K, Mehrabi Bahar M, Riazi-Esfahani H, Azarkish A, Farahani AD, Heidari M, et al. Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence. Int Ophthalmol. 2022;42:2017\u201328.","journal-title":"Int Ophthalmol"},{"key":"1199_CR25","doi-asserted-by":"publisher","first-page":"5078565","DOI":"10.1155\/2017\/5078565","volume":"2017","author":"Q Hu","year":"2017","unstructured":"Hu Q, Bai Y, Chen X, Huang L, Chen Y, Li X. Recurrence of retinopathy of prematurity in zone II stage 3+ after ranibizumab treatment: a retrospective study. J Ophthalmol. 2017;2017:5078565.","journal-title":"J Ophthalmol"},{"key":"1199_CR26","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","volume":"41","author":"C Iwahashi","year":"2021","unstructured":"Iwahashi C, Utamura S, Kuniyoshi K, Sugioka K, Konishi Y, Wada N, et al. Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity. Retina. 2021;41:2261\u20138.","journal-title":"Retina"},{"key":"1199_CR27","doi-asserted-by":"publisher","first-page":"19946","DOI":"10.1038\/s41598-023-47212-7","volume":"13","author":"L Wu","year":"2023","unstructured":"Wu L, Li M, Wang L, Yan H, Zhou Z, Fan J, et al. Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography. Sci Rep. 2023;13:19946.","journal-title":"Sci Rep"},{"key":"1199_CR28","doi-asserted-by":"publisher","first-page":"31097","DOI":"10.1038\/s41598-024-82445-0","volume":"14","author":"AC \u00dcnal","year":"2024","unstructured":"\u00dcnal AC, Ak\u0131dan M, Erol MK. A comparation of three different anti-VEGF drugs in development of persistent avascular retina in premature children. Sci Rep. 2024;14:31097.","journal-title":"Sci Rep"},{"key":"1199_CR29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.18240\/ijo.2019.09.22","volume":"12","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Liu TG, Li WY, Zhao MW, Liang JH. Fluorescein angiography of retinal vascular involution after intravitreal injection of ranibizumab for retinopathy of prematurity. Int J Ophthalmol. 2019;12:79\u201382.","journal-title":"Int J Ophthalmol"},{"key":"1199_CR30","doi-asserted-by":"publisher","first-page":"1202927","DOI":"10.3389\/fped.2023.1202927","volume":"11","author":"N Alva","year":"2023","unstructured":"Alva N, Mart\u00ednez AR, Ortiz-Saavedra B, Montes-Madariaga ES, Cotrina A, Caballero-Alvarado JA, et al. Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis. Front Pediatr. 2023;11:1202927.","journal-title":"Front Pediatr"},{"key":"1199_CR31","doi-asserted-by":"publisher","first-page":"e0225643","DOI":"10.1371\/journal.pone.0225643","volume":"14","author":"QQ Tan","year":"2019","unstructured":"Tan QQ, Christiansen SP, Wang J. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review. PLoS ONE. 2019;14:e0225643. https:\/\/doi.org\/10.1371\/journal.pone.0225643.","journal-title":"PLoS ONE"},{"key":"1199_CR32","doi-asserted-by":"publisher","first-page":"102567","DOI":"10.1016\/j.eclinm.2024.102567","volume":"71","author":"N Marlow","year":"2024","unstructured":"Marlow N, Reynolds JD, Lepore D, Fielder AR, Stahl A, Hao H, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial. EClinicalMedicine. 2024;71:102567.","journal-title":"EClinicalMedicine."},{"key":"1199_CR33","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1038\/s41433-020-01321-z","volume":"35","author":"Y Mori","year":"2021","unstructured":"Mori Y, Arima M, Ueda E, Fujiwara K, Seki E, Nakama T, et al. Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity. Eye (Lond). 2021;35:2820\u20135.","journal-title":"Eye (Lond)"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01199-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01199-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01199-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:03:21Z","timestamp":1757171001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01199-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01199-y","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Nakagawa, None; Y. Murayama, None; Y. Suzuki, None; A. Uchiyama, None; T. Suzuki, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}